Celyad SA (CYAD)’s Financial Results Comparing With resTORbio Inc. (NASDAQ:TORC)

Celyad SA (NASDAQ:CYAD) and resTORbio Inc. (NASDAQ:TORC) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celyad SA 17 0.00 N/A -7.01 0.00
resTORbio Inc. 9 0.00 N/A -1.37 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Celyad SA 0.00% 0% 0%
resTORbio Inc. 0.00% -33% -31%

Analyst Ratings

The Recommendations and Ratings for Celyad SA and resTORbio Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Celyad SA 0 0 0 0.00
resTORbio Inc. 0 0 1 3.00

Competitively the consensus target price of resTORbio Inc. is $23, which is potential 124.17% upside.

Institutional & Insider Ownership

Institutional investors owned 6.89% of Celyad SA shares and 54.1% of resTORbio Inc. shares. About 0.09% of Celyad SA’s share are owned by insiders. On the other hand, insiders owned about 38.1% of resTORbio Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Celyad SA -20.56% -5.33% -45.9% -45.8% -63.12% -37.44%
resTORbio Inc. 1.02% 5.73% 35.32% 22.11% -27.51% 26.22%

For the past year Celyad SA had bearish trend while resTORbio Inc. had bullish trend.


resTORbio Inc. beats on 4 of the 7 factors Celyad SA.

Celyad SA, a biopharmaceutical company, focuses on engineered cell therapy treatments. It operates in two segments, Cardiology and Immuno-oncology. The companyÂ’s lead product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure. Its lead product candidate in oncology disease is CAR-T NKR-2, an autologous chimeric antigen receptor (CAR) for the treatment of cancer. In addition, the companyÂ’s preclinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection catheter; heart access sheaths; mitral valve neo-chordaes; and closure devices. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.